Genmab — April 2018
-
I Mirror prøvede man 3, 30 og 60 mg. På CT står dosis størrelsen faktisk ikke for fase 3. Men her skriver de at 30 mg eller mere var bedst. https://mymsaa.org/publications/msresearch-update-2017/ofatumumab/
-
God morgen fra baglokalet i familiens butik i Rødovre Centrum.
-
Så er spørgsmålet om det vil give ekstra at tilføje dara http://onkologisktidsskrift.dk/behandlinger/lungekraeft/758-nsclc-patienter-overlever-med-lungekraeft-efter-tecentriq-behandling.html
-
Keytruda klarer sig også fint i nsclc. http://onkologisktidsskrift.dk/behandlinger/lungekraeft/763-peter-meldgaard-keytruda-kombination-oger-overlevelsen-markant-for-nsclc.html
-
Onclive article : Novel Approaches Emerge in AL Amyloidosis
https://www.onclive.com/web-exclusives/novel-approaches-emerge-in-al-amyloidosis -
Daratumumab (HuMax
-CD38) Safety Study in Multiple Myeloma - https://clinicaltrials.gov/ct2/show/study/NCT00574288?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=04%2F27%2F2018&rank=1§=X01256 - results posted -
most of these hospitals finished
recruiting now on this (D-RVd) trial, some even complete https://clinicaltrials.gov/ct2/show/study/NCT02874742?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=04%2F27%2F2018&rank=2&show_locs=Y#locn -
Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL (BOMP) was Terminated https://clinicaltrials.gov/ct2/show/NCT01612988?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=04%2F27%2F2018&rank=4
(which makes sense, it wasnt even a Novartis study) -
Onclive video : Dr. Voorhees on Treatments for Patients With Relapsed Multiple Myeloma
-
Very uplifting E L. They have also changed the primary completion date for the Griffin study from nov. 4. 2019 to dec. 31. 2018! A whole year. I wouldn't be surprised if they chose to file on that study. Even though it's only a phase 2. That would mean filing on the last frontline segment already next year.
-
E L & Bulder. So are so diligent, even in the weekends. Thanks a lot. We all profit from it....
-
You are so diligent,..
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind